Adverse Drug Events
23
1
1
18
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 23 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
28%
5 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (23)
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors
Improving Safety by Basic Computerizing Outpatient Prescribing
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
Drug-Related Problems : Focus on Age and Diabetes
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
Information Systems-enabled Outreach Program for Adverse Drug Events
Pharmacogenetic Testing Among Home Health Patients
Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge
Response to Medication Registry
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
YouScript IMPACT Registry
Impact of Medication Reconciliation Intervention on the Rate of Preventable Adverse Drug Events (ADEs) and Healthcare Utilization
Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes
Implementation of Real-time ADE Surveillance and Decision Support
Multi-Center Medication Reconciliation Quality Improvement Study
Patient Profiling and Provider Feedback to Reduce Adverse Drug Events
Reducing Adverse Drug Events in the Nursing Home